

Supplementary Data

Systematic Screening Study for the Selection of Proper Stabilizers to Produce Physically Stable Canagliflozin Nanosuspension by Wet Milling Method

Yagmur Pirincci Tok ¹, Burcu Mesut ², Sevgi Güngör ², Ali Osman Sarıkaya ³, Emre Erol Aldeniz ³, Udaya Dude ³ and Yıldız Özsoy ^{2,*}

¹ Institute of Health Sciences, Istanbul University, Istanbul 34216, Türkiye; yagmur.pirincci@ogr.iu.edu.tr

² Department of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University, Istanbul 34126, Türkiye; bmesut@istanbul.edu.tr (B.M.); sgungor@istanbul.edu.tr (S.G.)

³ Research and Development Center, Abdi İbrahim Pharmaceutical Company, İstanbul 34538, Türkiye; ali.sarikaya@abdiibrahim.com.tr (A.O.S.); emre.aldeniz@abdiibrahim.com.tr (E.E.A.); udaya.dude@abdiibrahim.com.tr (U.D.)

* Correspondence: yozsoy@istanbul.edu.tr; Tel.: +90-(212)-440-0272




Figure S1. Measurements of the particle size and PDI of grinding nanosuspension: **(a)** Particle size reduction profile versus time during milling and its stability over 1 month; **(b)** PDI values of final fresh nanosuspension and over 1 month



(a)



(b)

Figure S2. The degradation views of the first candidate optimum formulation: (a) front view; (b) top view

Table S1. The composition of additional trials and Z average particle size, PDI value

Sample Run	SLS% (w/w)	T80% (w/w)	P407% (w/w)	Particle size (mean nm \pm SD)	PDI (mean \pm SD)
T1	0.075	0.01	0.2	230.2 \pm 4.62	0.146 \pm 0.13
T2	0.075	0.01	0.5	266.8 \pm 11.37	0.196 \pm 0.22
T3	0.05	0.025	0.5	216.5 \pm 5.4	0.136 \pm 0.44
T4	0.022	0.082	0.2	217.0 \pm 3.36	0.118 0.43




Figure S3. The dissolution profile of the nanosuspension developed in pre-formulation study in non-sink conditions